Memry — NOBLE Investor Conference August 2007
30 slides from Memry's conference presentation, Aug 20, 2007
Slide 1: Memry NOBLE Investor Conference August 2007
MEMRY NOBLE Investor Conference August 2007
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements which involve known and unknown risks, uncertainties or other factors not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or
Slide 3: Compelling Value Proposition
Compelling Value Proposition Innovative, Strategic Technology Solutions Large and Growing Medical Device Market Strong Growing Pipeline Strong Balance Sheet Strong Cash Generator Building Momentum Trading Near Book Value
Slide 4: Enabling minimally invasive and targeted therapies for the medical industry
“Enabling minimally invasive and targeted therapies for the medical industry”
Slide 5: Materials & Processes Enabling Properties (Metals)
Materials & Processes Enabling Properties Superelastic & Shape Kink resistance Memory Nitinol Alloys Crush resistance Ability to recover large Wire & Tube Drawing deformation Laser Cutting Thermal Recovery Stent Manufacturing Confined Access & Delivery Wire Forming i Surface Finishing Low Constant U
Slide 6: Materials & Processes Enabling Properties (Polymers)
Materials & Processes Enabling Properties Custom Co-Extruded Multi Layer Polymer Components Multi Lumen Polyurethanes Coil and Braid Reinforcement Myers Thin Wall Polyesters : Fluoropolymers Jacketi ng Polyimides Radiopacity Tipping & Forming Tapering Grinding Braiding & Coiling Catheter-based Minim
Slide 7: Medical device market by segment
2005 MOrthopaedics lsurgery/Endosurgery Cardiovascular/Thoracic ® Surgical Devices & Instruments Monitoring/Imaging i Electrosurgical/Auxiliary Equipment @ Robotics (Source: BCC Research, June 2006)
Slide 8: Improving Quality of Healthcare
Improving Quality of Healthcare Aging Population Stringent Regulatory Environment Competition & Speed to Market Cost Containment Product Innovation & Technology Mergers & Acquisitions Globalization Vendor Base Consolidation
Slide 9: Device OEMs want to focus on R&D, Technology, Sales & Marketing
Device OEMs want to focus on R&D, Technology, Sales & Marketing, Distribution and Regulatory Issues Device companies outsource for a variety of reasons Reduce operating costs Expand their portfolio of capabilities Simplify supply chain logistics Reduce capital expenditures Larger, full-service suppl
Slide 10: Full Suite of Capabilities
Full Suite of Capabilities Supply Chain Management Technology Leadership Rapid Turnaround Quality & Competitive Pricing Device Application Knowledge Globalization
Slide 11: Device value chain
Finished Device Subassemblies & Assemblies Parts & Components ‘Semi-Finished Materials Raw Materials Metals Polymers Device Compan’ Device Company Stent grafts, surgical instruments, etc. eters, balloons, delivery sysi te Value Added Operations Value Added Operations Taser, grinding, EP, coiling, as
Slide 12: Revenue by market and product
P: : 57% li Vascular/Radiology EndoSurgery Coronary & EP MUrology/OBGYN Others Orthopaedics 27% Stents & Stent Grafts Catheters Endosurgical Instruments Bi Guidewires Others Embolic Protection Memry Corp., Estimated
Slide 13: Markets served
Neurology ® Ophthalmology Coronary & EP Vasfular/Radigiogy ow Endosurgery ; @ i Uroldgy/OBGyn re) | | 7 \ | Pp Pithopaedics \ | {
Slide 14: Materials, Processes & Product Integration
Materials, Processes & Product Integration High-end Processing Technologies Passive and Biointeractive Medical Polymers & Biomaterials Surface Modification & Finishing Technologies Integration Technologies Critical to Complete Product capability Vv Market Leadership & Recognition as Leading Provider
Slide 15: Laser capability upgrade
Laser capability upgrade Introduction of V2 ultra small diameter nitinol tubing Addition of plasma welding capability Launch of new product line, Putnam Plastics Plus Enhanced capability of guidewire finishing and coating
Slide 16: ISO 13485:2003 Certification for all plants
ISO 13485:2003 Certification for all plants (completed) Electropolishing capability and facility upgrade Addition of insert molding line for catheter manufacturing Addition of high volume hydrophilic coating line for guidewires Implementation fast turnaround tubing line
Slide 17: Management team
Robert Belcher, Chief Executive Officer Dean Tulumaris, President & Chief Operating Officer Richard Sowerby, Chief Financial Officer & Treasurer Philippe Poncet, Vice President Business Development Marcy Macdonald, Vice President Human Resources
Slide 18: Fiscal year and nine months financial summary
Fiscal Year Nine Months Ended 2005 A 2006 A 3/31/06A 3/31/07 A Revenue $45.0M $52.6M $39.3M $38.5M Gross Profit $17.9M $20.4M $15.6M $12.7M Gross Margin % 40% 39% 40% 33% Net Income $2.7M b) $2.7M a) $1.8M a)b) $0.3M a)b) Diluted EPS $0.10 $0.09 $0.06 $0.01 a) Includes $1.1M of CEO retirement charge
Slide 19: Revenue Growth
Revenue Growth (in millions) $34.4 $34.5 2000 2001 A 2002 2003 A 2004 A 2005 A 2006A 2007 P Fiscal Year
Slide 20: Nitinol Segment Quarterly Revenue
Nitinol Segment Quarterly Revenue (in thousands) Q105A 205A Q305A 405A Q10GA 206A Q306A 406A Q107A 207A Q307A aQso7P
Slide 21: Polymer Segment Quarterly Revenue
Polymer Segment Quarterly Revenue (in thousands) Q105A Q205A 305A Q405A Q106A QZ06A Q306A Q406A Q107A Q207A Q307A Q407P
Slide 22: Invest in areas to generate revenue growth
Invest in areas to generate revenue growth Development Projects New Technologies Sales & Marketing Look for cost improvement opportunities Insurance SEC, Legal Chemical Costs Achieve process efficiencies
Slide 23: R&D Investment
R&D Investment (in millions) ao 1.9 2.0 2004 A* 2005 A* 2006 A R&D Exp @R&D COGS * Putnam Plastics acquired in November 2004.
Slide 24: R&D Revenue
R&D Revenue (in millions) 2004 A* 2005 A* 2006 A 2007 P 4# R&D Revenue Total R&D Investment * Putnam Plastics acquired in November 2004.
Slide 25: R&D Projects
R&D Projects Metals @ Plastics
Slide 26: Balance sheet March 2007
March 2007A Current Assets $21.3 Property, Plant & Equipment E 8.9 Goodwill & Other Intangibles Other Assets Total Assets Current Liabilities Notes Payable, less current maturities Non-current Liabilities Stockholders Equity Total Liabilities and Stockholders Equity Total Debt
Slide 27: EBITDA and Adjusted EBITDA definitions
In this presentation, the Company refers to EBITDA and Adjusted EBITDA, financial measures that are not recognized under accounting principles generally accepted in the United States of America (“GAAP”). The Company defines EBITDA as earnings before income taxes, interest expense, net, depreciation
Slide 28: EBITDA reconciliation, nine months ended
Nine Months Ended 03/31/06A 03/31/07. Revenue $39.3 $38.5 Net Income $1.8 $0.3 + Income Taxes Ay d 1.1 0.1 + Interest Expense, Net 1.0 : 0.8 0.6 + Depreciation 19 5 1.6 1.7 + Amortization (a) 0.6 k 0.5 0.5 EBITDA $7.9 $3.2 + Incremental Litigation and Professional Fees (b) 04 0.2 + CEO Retirement (c
Slide 29: EBITDA reconciliation footnotes
a) Amortization excludes the amortization of deferred financing costs, which is included in interest expense, net. b) The Company incurred incremental fees for litigation and professional fees for litigation defense and the voluntary implementation of Sarbanes-Oxley Section 404 compliance. c) Effect
Slide 30: Compelling Value Proposition
Compelling Value Proposition Innovative, Strategic Technology Solutions Large and Growing Medical Device Market Strong Growing Pipeline Strong Balance Sheet Strong Cash Generator Building Momentum Trading Near Book Value